Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04664127Completed

Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel

Role: lead

NCT04651491Completed

Treatment of Influenza and ARVI in Children by Kagocel ®

Role: lead

NCT04626622Completed

Kagocel® for the Prevention of ARVI and Influenza in Young People

Role: lead

NCT04611061Completed

Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers

Role: lead

NCT03036163Phase 1Completed

Phase 1 Study of PBTZ169

Role: lead

NCT03334734Phase 2Terminated

Phase 2a Study of PBTZ169

Role: lead

NCT04150224Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

Role: lead

NCT03677258Not ApplicableCompleted

Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy

Role: lead

NCT02983019Completed

Treatment of Influenza in Routine Clinical Practice

Role: lead

All 9 trials loaded